# Piero Ruggenenti

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/piero-ruggenenti/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,042 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 81 |
| i10-index | 216 |
| OpenAlex ID | https://openalex.org/A5059276594 |
| ORCID iD | https://orcid.org/0000-0002-8394-0879 |
| Works | 328 |

## Researcher papers

- [Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis](https://scholariq.org/papers/pharmacological-blood-pressure-lowering-for-primary-and-secondary-prevention-of/)
- [Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial](https://scholariq.org/papers/blood-pressure-control-for-renoprotection-in-patients-with-non-diabetic-chronic/)
- [Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease](https://scholariq.org/papers/fatty-kidney-emerging-role-of-ectopic-lipid-in-obesity-related-renal-disease/)
- [Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials](https://scholariq.org/papers/change-in-albuminuria-as-a-surrogate-endpoint-for-progression-of-kidney-disease/)
- [Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy](https://scholariq.org/papers/anti-phospholipase-a2-receptor-antibody-titer-predicts-post-rituximab-outcome-of/)
- [Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis](https://scholariq.org/papers/age-stratified-and-blood-pressure-stratified-effects-of-blood-pressure-lowering/)
- [Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome](https://scholariq.org/papers/rituximab-in-steroid-dependent-or-frequently-relapsing-idiopathic-nephrotic/)
- [Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial](https://scholariq.org/papers/early-detection-of-diabetic-kidney-disease-by-urinary-proteomics-and-subsequent/)
- [Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides](https://scholariq.org/papers/diagnosis-and-prediction-of-ckd-progression-by-assessment-of-urinary-peptides/)
- [Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes](https://scholariq.org/papers/non-proteinuric-pathways-in-loss-of-renal-function-in-patients-with-type-2/)
- [Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy](https://scholariq.org/papers/safety-of-rituximab-compared-with-steroids-and-cyclophosphamide-for-idiopathic/)
- [A meta-analysis of GFR slope as a surrogate endpoint for kidney failure](https://scholariq.org/papers/a-meta-analysis-of-gfr-slope-as-a-surrogate-endpoint-for-kidney-failure/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Renin-Angiotensin System Studies](https://scholariq.org/topics/renin-angiotensin-system-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.